Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database
Open Access
- 22 March 2024
- journal article
- research article
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 117, 253-260
Abstract
No abstract availableKeywords
Funding Information
- Basic Public Welfare Research Program of Zhejiang Province (LGD20H310002)
- National Natural Science Foundation of China (81903584)
This publication has 59 references indexed in Scilit:
- Antiseizure Medications for Adults With EpilepsyJAMA, 2022
- RhabdomyolysisDisease-a-Month, 2020
- The Risk of Specific Congenital Anomalies in Relation to Newer Antiepileptic Drugs: A Literature ReviewDrugs - Real World Outcomes, 2016
- A case of rhabdomyolysis in which levetiracetam was suspected as the causeEpilepsy & Behavior Case Reports, 2014
- Levetiracetam: A Possible New Inducer of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in 2 CasesJAMA Dermatology, 2013
- Drug–drug interaction between methotrexate and levetiracetam in a child treated for acute lymphoblastic leukemiaPediatric Blood & Cancer, 2012
- Drug induced rhabdomyolysisCurrent Opinion in Pharmacology, 2012
- Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant proteinEuropean Journal of Pharmacology, 2006
- A novel mechanism underlying drug resistance in chronic epilepsyAnnals of Neurology, 2003
- Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugsPharmacological Research, 2000